HALOZYME THERAPEUTICS, INC. Proceeds from Sale and Maturity of Debt Securities, Available-for-sale
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities · last filed 2026-02-17
- HALOZYME THERAPEUTICS, INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2025 was $722.25M, a 82.58% increase from fiscal 2024.
- HALOZYME THERAPEUTICS, INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2024 was $395.57M, a 87.21% increase from fiscal 2023.
- HALOZYME THERAPEUTICS, INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2023 was $211.30M, a 71.68% decline from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2022 was $746.13M, a 201.24% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 12 month |
|---|---|
| 2025-12-31 | $722.25M 10-K · filed 2026-02-17 |
| 2024-12-31 | $395.57M 10-K · filed 2026-02-17 |
| 2023-12-31 | $211.30M 10-K · filed 2026-02-17 |
| 2022-12-31 | $746.13M 10-K · filed 2025-02-18 |
| 2021-12-31 | $247.68M 10-K · filed 2024-02-20 |